Aerovate Therapeutics Inc. (AVTE) NASDAQ

$24.30 -0.16 (-0.65%)

Market Cap: $597.08M

As of 08/10/22 04:00 PM EDT. Market closed.

(AVTE)

Aerovate Therapeutics Inc. (AVTE) NASDAQ

$24.30 -0.16 (-0.65%)

Market Cap: $597.08M

As of 08/10/22 04:00 PM EDT. Market closed.

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or ... read more

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH. read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Full Time Employees
2,021
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$25.15
Previous Close
$24.46
Days Range
$22.59 - $24.88
52 week range
$7.74 - $27.83
Volume
66,461
Avg. Volume (30 days)
157,040
Market Cap
$597.08M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
24,410,393
Open
$25.15
Previous Close
$24.46
Days Range
$22.59 - $24.88
52 week range
$7.74 - $27.83
Volume
66,461
Avg. Volume (30 days)
157,040
Market Cap
$597.08M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
24,410,393

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR AEROVATE THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Dake Benjamin T See Remarks Aug 08, 2022 Option Exercise $1.74 6,943 12,081 6,943 Aug 10, 2022, 05:15 PM
Dake Benjamin T See Remarks Aug 09, 2022 Option Exercise $1.74 8,700 15,138 8,700 Aug 10, 2022, 05:15 PM
Dake Benjamin T See Remarks Aug 09, 2022 Sale $24.06 8,700 209,325 2,791 Aug 10, 2022, 05:15 PM
Dake Benjamin T See Remarks Aug 08, 2022 Sale $24.62 6,943 170,962 2,954 Aug 10, 2022, 05:15 PM
Cormorant Asset Management, LP Former 10% Owner Jul 02, 2021 Buy $14.00 500,000 7,000,000 2,030,691 Jul 07, 2021, 04:45 PM
RA CAPITAL MANAGEMENT, L.P. Director Jul 02, 2021 Buy $14.00 2,785,714 38,999,996 6,965,568 Jul 06, 2021, 05:03 PM
Sofinnova Venture Partners X, L.P. 10% Owner Jul 02, 2021 Buy $14.00 357,142 4,999,988 3,758,686 Jul 06, 2021, 04:28 PM
Katabi Maha Director Jul 02, 2021 Buy $14.00 357,142 4,999,988 3,758,686 Jul 06, 2021, 04:27 PM
GRAYZEL DAVID S. Director Jul 02, 2021 Buy $14.00 535,714 7,499,996 3,103,879 Jul 06, 2021, 04:27 PM
Atlas Venture Fund XII, L.P. 10% Owner Jul 02, 2021 Buy $14.00 535,714 7,499,996 3,103,879 Jul 06, 2021, 04:26 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Dake Benjamin T See Remarks 08/08/2022 12,081
Dake Benjamin T See Remarks 08/09/2022 15,138
Dake Benjamin T See Remarks 08/09/2022 209,325
Dake Benjamin T See Remarks 08/08/2022 170,962
Cormorant Asset Management, LP Former 10% Owner 07/02/2021 7,000,000
RA CAPITAL MANAGEMENT, L.P. Director 07/02/2021 38,999,996
Sofinnova Venture Partners X, L.P. 10% Owner 07/02/2021 4,999,988
Katabi Maha Director 07/02/2021 4,999,988
GRAYZEL DAVID S. Director 07/02/2021 7,499,996
Atlas Venture Fund XII, L.P. 10% Owner 07/02/2021 7,499,996
Load More Insider Transactions